Costs of Clinical Events in Type 2 Diabetes Mellitus Patients in the Netherlands: A Systematic Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Sep 7

PMID 31490989

Citations 5

Authors

Alexander V van Schoonhoven

Judith J Gout-Zwart

Marijke J S de Vries

Antoinette D I van Asselt

Evgeni Dvortsin

Pepijn Vemer

Job F M van Boven

Maarten J Postma

Affiliations

Soon will be listed here.

Abstract

Background: Type 2 diabetes mellitus (T2DM) is an established risk factor for cardiovascular and nephropathic events. In the Netherlands, prevalence of T2DM is expected to be as high as 8% by 2025. This will result in significant clinical and economic impact, highlighting the need for well-informed reimbursement decisions for new treatments. However, availability and consistent use of costing methodologies is limited.

Objective: We aimed to systematically review recent costing data for T2DM-related cardiovascular and nephropathic events in the Netherlands.

Methods: A systematic literature review in PubMed and Embase was conducted to identify available Dutch cost data for T2DM-related events, published in the last decade. Information extracted included costs, source, study population, and costing perspective. Finally, papers were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).

Results: Out of initially 570 papers, 36 agreed with the inclusion criteria. From these studies, 150 cost estimates for T2DM-related clinical events were identified. In total, 29 cost estimates were reported for myocardial infarction (range: €196-€27,038), 61 for stroke (€495-€54,678), fifteen for heart failure (€325-€16,561), 24 for renal failure (€2,438-€91,503), and seventeen for revascularisation (€3,000-€37,071). Only four estimates for transient ischaemic attack were available, ranging from €587 to €2,470. Adherence to CHEERS was generally high.

Conclusions: The most expensive clinical events were related to renal failure, while TIA was the least expensive event. Generally, there was substantial variation in reported cost estimates for T2DM-related events. Costing of clinical events should be improved and preferably standardised, as accurate and consistent results in economic models are desired.

Citing Articles

Trends in Cardiovascular Diseases and Costs Among Type 2 Diabetes Mellitus (T2DM) Patients in Malaysia: A Cohort Study of 240,611 Public Hospital Inpatients.

Kamarudin N, Wan Puteh S, Abd Manaf M, Shahari M Cureus. 2025; 16(12):e75531.

PMID: 39803007 PMC: 11721057. DOI: 10.7759/cureus.75531.

Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands.

Quist S, van Schoonhoven A, Bakker S, Pochopien M, Postma M, van Loon J Cardiovasc Diabetol. 2023; 22(1):328.

PMID: 38017448 PMC: 10685667. DOI: 10.1186/s12933-023-02053-6.

Non-adherence to guideline recommendations for insulins: a qualitative study amongst primary care practitioners.

Dankers M, van den Berk-Bulsink M, van Dalfsen-Slingerland M, Nelissen-Vrancken H, Mantel-Teeuwisse A, van Dijk L BMC Prim Care. 2022; 23(1):150.

PMID: 35698052 PMC: 9189803. DOI: 10.1186/s12875-022-01760-5.

Incidence of myocardial infarction in people with diabetes compared to those without diabetes: a systematic review protocol.

Narres M, Kvitkina T, Claessen H, Ubach E, Wolff G, Metzendorf M Syst Rev. 2022; 11(1):89.

PMID: 35550681 PMC: 9097115. DOI: 10.1186/s13643-022-01962-z.

Identifying and delineating the type 2 diabetes population in the Netherlands using an all-payer claims database: characteristics, healthcare utilisation and expenditures.

Geurten R, Elissen A, Bilo H, Struijs J, van Tilburg C, Ruwaard D BMJ Open. 2021; 11(12):e049487.

PMID: 34876422 PMC: 8655569. DOI: 10.1136/bmjopen-2021-049487.

References

Johannesson M, Jonsson B, Kjekshus J, Olsson A, Pedersen T, Wedel H . Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997; 336(5):332-6. DOI: 10.1056/NEJM199701303360503. View

van Exel J, Koopmanschap M, van Wijngaarden J, Scholte Op Reimer W . Costs of stroke and stroke services: Determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Eff Resour Alloc. 2003; 1(1):2. PMC: 156021. DOI: 10.1186/1478-7547-1-2. View

Boyne J, van Asselt A, Gorgels A, Steuten L, De Weerd G, Kragten J . Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study. J Telemed Telecare. 2013; 19(5):242-8. DOI: 10.1177/1357633X13495478. View

Soekhlal R, Burgers L, Redekop W, Tan S . Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J. 2013; 21(5):230-5. PMC: 3636331. DOI: 10.1007/s12471-013-0386-y. View

Vaidya A, Severens J, Bongaerts B, Cleutjens K, Nelemans P, Hofstra L . High-sensitive troponin T assay for the diagnosis of acute myocardial infarction: an economic evaluation. BMC Cardiovasc Disord. 2014; 14:77. PMC: 4065542. DOI: 10.1186/1471-2261-14-77. View

Osnabrugge R, Magnuson E, Serruys P, Campos C, Wang K, van Klaveren D . Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. Heart. 2015; 101(24):1980-8. DOI: 10.1136/heartjnl-2015-307578. View

Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer B . Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. J Med Econ. 2016; 19(8):742-9. DOI: 10.3111/13696998.2016.1167695. View

Postmus D, Pari A, Jaarsma T, Luttik M, Van Veldhuisen D, Hillege H . A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J. 2011; 162(6):1096-104. DOI: 10.1016/j.ahj.2011.09.019. View

Jacobs M, Kaasenbrood F, Postma M, van Hulst M, Tieleman R . Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Europace. 2016; 20(1):12-18. DOI: 10.1093/europace/euw285. View

10.

Boersma C, Gansevoort R, Pechlivanoglou P, Visser S, van Toly F, de Jong-van den Berg L . Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Clin Ther. 2010; 32(6):1103-21. DOI: 10.1016/j.clinthera.2010.06.013. View

11.

van der Mei S, Kuiper D, Groothoff J, van den Heuvel W, van Son W, Brouwer S . Long-term health and work outcomes of renal transplantation and patterns of work status during the end-stage renal disease trajectory. J Occup Rehabil. 2011; 21(3):325-34. PMC: 3173627. DOI: 10.1007/s10926-011-9317-1. View

12.

Heyde G, Koch K, de Winter R, Dijkgraaf M, Klees M, Dijksman L . Randomized trial comparing same-day discharge with overnight hospital stay after percutaneous coronary intervention: results of the Elective PCI in Outpatient Study (EPOS). Circulation. 2007; 115(17):2299-306. DOI: 10.1161/CIRCULATIONAHA.105.591495. View

13.

Hunt B, Glah D, van der Vliet M . Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands. Diabetes Ther. 2017; 8(4):753-765. PMC: 5544604. DOI: 10.1007/s13300-017-0266-3. View

14.

Tiemann O . Variations in hospitalisation costs for acute myocardial infarction - a comparison across Europe. Health Econ. 2008; 17(1 Suppl):S33-45. DOI: 10.1002/hec.1322. View

15.

Corro Ramos I, M Versteegh M, de Boer R, Koenders J, Linssen G, Meeder J . Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch.... Value Health. 2017; 20(10):1260-1269. DOI: 10.1016/j.jval.2017.05.013. View

16.

van Hout B, Simoons M . Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?. Eur Heart J. 2001; 22(9):751-61. DOI: 10.1053/euhj.2000.2308. View

17.

Isaaz K, Coudrot M, Sabry M, Cerisier A, Lamaud M, Robin C . Return to work after acute ST-segment elevation myocardial infarction in the modern era of reperfusion by direct percutaneous coronary intervention. Arch Cardiovasc Dis. 2010; 103(5):310-6. DOI: 10.1016/j.acvd.2010.04.007. View

18.

Stevanovic J, Denee L, Koenders J, Postma M . Incidence Description and Costs of Acute Heart Failure in the Netherlands. Value Health. 2016; 17(7):A328. DOI: 10.1016/j.jval.2014.08.597. View

19.

Baeten S, van Exel N, Dirks M, Koopmanschap M, Dippel D, Niessen L . Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Cost Eff Resour Alloc. 2010; 8:21. PMC: 2998455. DOI: 10.1186/1478-7547-8-21. View

20.

Clarke P, Leal J, Kelman C, Smith M, Colagiuri S . Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health. 2008; 11(2):199-206. DOI: 10.1111/j.1524-4733.2007.00228.x. View